The lower response exhibited by patients with this subtype of mutation is consistent with previous studies, although further studies are needed to confirm the role of MAP2K1 class III mutations as a driver of resistance to MEK inhibitors in patients with histiocytic neoplasms. This evidence concerns the gene MAP2K1 and histiocytic neoplasm.